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Amino acid-functionalised calixarenes as crystal growth modifiers 
Calix[4]arenes functionalised at the upper rim with acidic amino acid residues are 
found to have a significant impact on the crystal growth of model mineral 
systems, calcium carbonate and barium sulfate. The aspartic acid derivative is 
found to be most efficacious, matching or exceeding the impact of commercial 
phosphonate-based scale inhibitors. In some cases, the modified morphologies 
are found to be similar to those induced by proteins isolated from biomineralised 
systems.  




Crystallisation is a fascinating phenomenon in Nature and is of great importance to 
many industrial processes. It is therefore of no surprise that it is a highly active area of 
research for both natural and artificial systems. Additives are one of the many methods 
used by industry to control crystallisation of the desired inorganic products(1, 2) and 
inhibit unwanted scale formation.(3) However, Nature has had a much longer time to 
adapt biomineralisation processes to changing functions of various biominerals and can 
control biomineral formation with much greater finesse.(4, 5) Studying how Nature 
produces such intricate biominerals may provide strategies in preparing new and 
improved materials and crystal growth modifiers.(6-9) 
There is a vast amount of literature describing a variety of biomineral systems, 
however a complete biomineralisation mechanism is elusive and it is remarkable that a 
small amount of organic material (comprising proteins and polysaccharides) can have 
such a large influence over the mineral formation and properties. For example, mollusc 
shells have ~5% organic content(10, 11) which exerts control over the crystallisation of 
calcium carbonate(10, 12) and gives nacre its unusual mechanical properties(13). One 
of the emerging themes is that the proteins and organic matrices involved in the 
formation of biominerals, particularly those associated with calcium carbonate minerals, 
are of above-average acidity. Many of the these acidic proteins are enriched in aspartic 
acid and glutamic acid residues with a preference for the former one over other acidic 
amino acids.(14-16)  
Inspired by these observations, the impact of acidic residues, such as aspartic 
and glutamic acids, and other organic acids have been studied. Dalas et al. found that 





 and stabilise vaterite. Later work by Wu et al.(19) with a selection of 
4 
 
the same amino acids (e.g. aspartic acid, glutamic acid) and organic acids (e.g. succinic 
acid, acetic acid, glutaric acid) showed the impact of these additives on etch pit 
morphology during the dissolution of calcite. Their results suggested that the geometry 
of the additives was important, in particular the distance between calcite surface binding 
groups (ammonium and carboxylic acid). Elhadj et al. showed that the hydrophilicity 
and net molecular charge of peptides can be used to predict induced growth rate 
enhancement of calcite, resulting from a reduced diffusion barrier due to displacement 
of water molecules at the surface.(20) Modelling studies have shown that even the 
aspartic acid monomer can act as a catalyst enhancing the crystal growth rate of barite at 
appropriate concentrations.(21)  
In addition to small molecule studies, many researchers have used artificial 
polymers to mimic natural biomacromolecules found associated with biominerals.(22-
24) Another approach to spatially arrange moieties known to control crystal growth is to 
use a macrocyclic, rather than polymeric, framework. While quite different to the 
natural systems, macrocycles can be functionalised with a number of active groups, and 
the structure, flexibility, and solubility can be readily controlled. The readily-
functionalised calixarenes are an attractive option in this context. Both calixarene and 
resorcinarene frameworks have, in fact, previously been used as crystal growth 
modifiers. Volkmer et al.(25-28) crystallised calcium carbonate underneath monolayers 
of amphiphilic resorcinarenes and calixarenes at the air-water interface. By changing 
the surface pressure, different polymorphs of calcium carbonate crystallised underneath 
monolayers. From these experiments Volkmer et al.(29) proposed that by varying the 
charge densities of the monolayers, the desired polymorph of calcium carbonate could 
be selectively crystallised. Crystallisation of inorganic minerals underneath monolayers 
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is of interest as biomimetics for oriented crystallisation at the biomineral–organic matrix 
interface.(30-33) 
Baynton et al.(34) functionalised the upper-rim of calix[4]arenes with sulfonate 
and phosphonate groups (Figure 1). The phosphonate derivative 1 was found to be more 
potent crystal growth modifier than the sulfonate compound 2, as expected, since 
phosphonates are typically potent crystal growth modifiers for barium sulfate.(35, 36) 
They noted that the phosphonate 1 was able to inhibit barium sulfate crystallisation 
completely even at 13–14 μM concentration while the sulfonate 2 only achieved 34% 
inhibition at 200 μM. The ability of calix[4]arene 1 to direct all its phosphonate groups 
along a surface contributes to its potency, and its efficacy is comparable to that of other 
small molecule phosphonate inhibitors; hydroxyethylenediphosphonic acid (HEDP), 
and ethylenediaminetetraphosphonic acid (EDTP), can achieve complete inhibition of 
barium sulfate at 24 μM and 1 μM respectively.  
 
Figure 1. Phosphonate (1) and sulfonate (2) functionalized calix[4]arenes investigated 
by Massi et al.(37) 
 
Heywood and Ovens(38) studied the impact of O-alkylated derivatives of p-
sulfonato calix[4]arenes, as the water soluble sodium salt, on calcium carbonate. The 
authors found that the dominant phase changed from vaterite to calcite as the alkyl 
chain length of the additive increased.  
Quite interestingly, Bartlett et al.(39) showed that amino acid functionalised 
calix[4]arenes (3–6, Figure 2) were more effective crystal growth modifiers of calcium 
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carbonate and calcium oxalate than the equivalent concentration of the amino acid 
monomers. Furthermore, the aspartic acid derivative (5) was more potent than the 
alanine (3) or the sarcosine (4) calix[4]arene derivatives. Following from this earlier 
work, Jones, et al.,(40) investigated the impact of aspartic acid (5) and glutamic acid (6) 
functionalised calix[4]arenes on calcium carbonate, barium sulfate, and calcium oxalate. 
Calix[4]arenes 5 and 6 were found to have an impact on the morphology and 
crystallisation kinetics of the model minerals investigated at very low concentrations 
(<1.5 μM); the aspartic acid derivative 5 was more potent than the glutamic acid 
derivative 6. 
 
Figure 2. Lower-rim functionalised calix[4]arene investigated by Bartlett, et al.(39) (3–
6) and Jones, et al.(40) (5, 6) for crystal growth modification properties of inorganic 
minerals.  
Amino acids can also be linked at the upper-rim of calix[4]arenes(41-43). This may 
allow for different flexibility and spatial arrangement of amino acids compared to 
attachment at the lower-rim of calix[4]arenes. Here, we report the syntheses of 
calix[4]arenes 7a-c, Figure 3. Calixarenes 7a and 7b are functionalised with aspartic 
acid and glutamic acid respectively. Calixarene 7c, functionalised with iminodiacetic 
acid, is a structural isomer of 7a, which lacks chirality and has a tertiary amide linkage. 
The impact of these amino acid functionalised calixarenes on model mineral systems, 
7 
 
calcium carbonate and barium sulfate, were investigated and the results are presented 
here. 
 
Figure 3. Upper-rim functionalised calix[4]arene used in this project to study the effects 
of acidic amino acids on the crystallisation of inorganic minerals. Here, the calixarenes 
were functionalised with aspartic acid (7a), glutamic acid (7b), and imino diacetic acid 
(7c) and locked in the cone conformer with propyl chains. 
2 Results and Discussion 
2.1 Synthesis 
Calixarenes 7a-c were prepared following well established procedures for 
functionalising the upper rim of the calixarene with amino acids and peptides (Scheme 
1).(41) The calix[4]arene was locked into the cone conformation by alkylation at the 
lower rim with propyl groups. Formylation of the upper rim, followed by oxidation, 
gave the carboxylic acid (8).(41) This was then activated with oxalyl chloride and DMF 
to give the acid chloride (9), which was then made to react with the C-protected amino 
acids (10–12). The intermediate esters 7a-c were fully characterised, and the results 
were entirely consistent with the proposed structures. The ester groups were then 
carefully hydrolysed to give the target amino acid functionalised calixarenes 7a-c. As 
the yield of the glutamate derivative (13b) was low (34%) alternative syntheses directly 
from the acid (8) using peptide-coupling reagents were investigated.(41) Treatment of 
the calixarene acid (8) with dicyclohexylcarbodiimide and N-hydroxybenzotriazole 
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followed by diethyl glutamate afforded the calixarene derivative (13b) in a slightly 
improved yield (41%), while using O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
hexafluorophosphate as the activating agent, gave a moderate yield (53%) of the desired 
derivative.  
  
Scheme 1. Preparation of upper-rim, amino acid functionalized calix[4]arene as 
additives for crystal growth modification 
The calixarene additives, 7a–c, are referred to in the subsequent sections as the 
carboxylic acids, as this is the form in which they were isolated. It should be noted, 
however, that the crystal growth studies were carried out at pH 6 for barite, with higher 
pH values known to be found in the gas diffusion calcium carbonate experiments.(44) 
Considering the protonation constants of a monomeric analogue such as N-acetyl 
aspartic acid (pKa1 = 3.04, pKa2 = 4.49)(45), it is probable that the additives will be 
substantially deprotonated when interacting with the crystal surfaces. While the impact 
of pH is beyond the scope of this study, previous studies have shown that the efficacy of 
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carboxylate modifiers decrease with decreasing pH, consistent with the carboxylate 
being the active moiety.(46) 
2.2 Impact on calcium carbonate crystallisation 
Calcium carbonate was crystallised using the gas-diffusion method.(47) This method of 
calcium carbonate crystallisation has a well known sequence progressing from the 
crystallisation of spherical vaterite or needle-like aragonite, which subsequently 
undergoes a solution-mediated transformation to rhombohedral calcite.(48) In the 
absence of additives, calcium carbonate precipitated predominantly as calcite 
(Figure 4a) with the typical rhombohedral shape; however, vaterite was observed in a 
few instances (Figure 4b). The calixarene additives, 7a–c, altered the morphology of 
calcite, even at concentrations less than 1 ppm. 
The L-aspartic acid additive 7a was more potent than 7b and 7c. The impact of 
7a was evident even at the lowest concentration investigated (0.4 μM, Figure 4c). 
Above 1.2 μM (Figure 4e) any indication of the general rhombohedral profile was lost. 
Similarly, the edges became more rounded with increasing additive concentrations as 
found for an aspartic acid rich protein.(49) In contrast to calcite particles grown in the 
presence of the lower-rim analogue 5 (Figure 2), the calcite particles here did not 
exhibit notches along the edges of the rhombohedron. 
The L-glutamic derivative 7b appeared to have less impact on the morphology 
of the calcite particles than 7a. The calcite particles grown in the presence of 7b showed 
notches along one corner (Figure 4f) or edge (Figure 4h) of the rhomb and had 
microsteps along the faces. At the highest concentration studied (1.2 μM) (Figure 4h), 
the calcite rhomb retained much of its edges with mild stepped faces like those grown in 
the presence of the lower-rim analogue 6 at 1.4 μM. However, the upper-rim 
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calix[4]arene 7b appears to be more potent than the lower-rim calix[4]arene 6. The 
stepped morphology resembles that of calcite grown in the presence of nacre proteins 
(isolated from the aragonitic layer of red abalone, Haliotis rufescens), in particular the 
aspartic acid/asparagine- and glycine-rich protein ‘AP8’.(50, 51) 
The iminodiacetic acid derivative 7c required a greater concentration to have an 
impact on the calcite morphology. At concentrations of 0.8 μM of 7c, stepped faces 
begin to appear on the calcite particles (Figure 4j); at lower concentrations, the calcite 
particles appeared to retain the typical rhombohedral shape (not shown here). 
Interestingly, spherical particles (Figure 4i), presumably vaterite, were also observed for 
calcium carbonate grown in the presence of 7c (0.4 μm). Vaterite phases have been 
known to be stabilised by aspartic acid,(17) glutamic acid,(18) poly(aspartic acid)(52) 
and egg ovalbulmin(53) preventing it from transforming into calcite. Calixarene 7c was 








   
   
   
Figure 4. SEM micrographs of calcium carbonate in the absence of additives: (a) calcite 
(major polymorph) and (b) vaterite (observed occasionally). Calcite morphology in the 
presence of amino acid functionalised calix[4]arene: L-Asp 7a at (c) 0.4 μM, (d) 
0.8 μM, (e) 1.2 μM; L-Glu 7b at (f) 0.4 μM, (g) 0.8 μM, (h) 1.2 μM; iminodiacetate 7c 
at (i) 0.4 μM, (j) 0.8 μM, (k) 1.2 μM. 
(c) (d) (e) 
(f) (g) (h) 




2.3  Impact on barium sulfate crystallisation 
2.3.1 Impact on crystal growth kinetics 
The impact of calix[4]arene additives 7a and 7b on barium sulfate crystallisation was 
first determined by desupersaturation experiments.(54) Here, the crystallisation process 
was followed by monitoring the decrease of conductivity vs time of a supersaturated 
solution of barium sulfate. The rates determined from these experiments were then 
plotted as a function of additive concentration (Figure 5); the aspartic acid derivative 7a 
was found to be approximately ten times more potent than the glutamic acid derivative 
7b at inhibiting barium sulfate crystallisation. The calixarene 7a was able to achieve 
complete inhibition (over the time scale of the experiment) at 0.3 μM whereas 7b 
required 3.9 μM to do the same. The glutamic acid derivative 7b has a comparable 
inhibition potency with respect to to the lower-rim derivative 5 (which achieved 
complete inhibition at 3.6 μM). On the other hand, the aspartic acid derivative 7a is at 
least ten times more potent than its lower-rim analogue 6 (which achieved complete 
inhibition at 3.6 μM). Calix[4]arene 7a is even slightly more potent than the 
phosphonate calixarene 1 (complete inhibition at 13–14 μM) and is approaching the 
efficacy of some organophosphonate inhibitors; under the conditions used here, HEDP 




Figure 5. Desupersaturation rates of a supersaturated barium sulfate solution as a function of the 
concentration of upper-rim amino acid functionalised calix[4]arene additives 7a and 7b. 
 
While aspartic and glutamic acids are often associated together as ‘acidic 
components’ in proteins associated with biominerals,(55) some authors have observed 
differences in the impact of the two amino acids(56) and their homo-oligomers.(57). Of 
the additives described here, it may be that the aspartic acid groups at the upper rim of 
calix[4]arene give a more appropriate bite and therefore a better chelating ability to 
barium ions on the surface of the nucleating crystals, thus efficiently inhibiting 
crystallization.  The higher inhibition potency of 7a compared to 5 could be ascribed to 
the different distances of the COOH groups of aspartic acid at the upper compared to 
those of the lower rim derivatives. 
2.3.2 Impact on barium sulfate morphology 
The morphologies of the barium sulfate crystals produced in the 
desupersaturation experiments were investigated. In the absence of any additives, the 
barium sulfate particles had the expected ‘pillow-shaped’ morphology with rounded 
(hk0) faces and (001) ends (Figure 6a). The two additives investigated here, 7a and 7b, 
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showed only some moderate impact on the morphology of barium sulfate but were 
highly potent in the inhibition of barium sulfate crystallisation. 
Barium sulfate grown in the presence of 7a was found to form polycrystalline 
assemblies. These crystals (Figure 6) were isolated at the end of the desupersaturation 
experiments. At additive levels of 0.16 μM and less, some of the clusters appeared 
lengthened along the c-axis exceeding the typical 2:1 c/a aspect ratio (refer to Jones et 
al.(58) for micrographs of control barium sulfate particles at S = 25). At higher 
concentrations the barium sulfate particles are smaller and have distorted morphologies; 
this is especially true at additive levels of 0.8 μM (Figure 6h). This is consistent with 
the inhibitory effect of the additive. Where the desupersaturation experiments did not 
result in a precipitate at the end of the experiment (at additive levels greater then 
0.8 μM), an aliquot of the solution was allowed to stand for up to 15 days over a 
microscope slide. Only at additive levels of 0.16 μM (Figure 6d,e) were polycrystalline 
‘ribbons’ observed. The ‘ribbons’ appeared to be comprised of smaller orthorhombic-
like particles. These polycrystalline ‘ribbons’ resemble results obtained by Heywood 
and Mann(59, 60) who crystallised barium sulfate underneath compressed n-eicosyl 
sulfate monolayers (43–47 mN m
−1
) with the (100) face parallel to the monolayer. 
However, it is not clear from the micrographs (Figure 6d,e) if there is selectivity for a 
particular crystal face. The morphology of barium sulfate crystallised in the presence of 
7a retained its typical rectangular shape (at concentrations less than 0.31 μM): in 
contrast barium sulfate crystallised in the presence of the lower-rim analogue 5 had 
elongated morphologies. Both aspartic acid-based additives resulted, however, in 
polycrystalline barium sulfate particles. 
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Figure 6. SEM micrographs showing the impact on the morphology of barium sulfate 
by L-Asp calix[4]arene 7a at, (a) 0 μM (control), (b) 0.04 μM, (c) 0.08 μM, (d) 
0.16 μM, (e) 0.16 μM close-up, (f) 0.31 μM, (g) 0.49 μM, and (h) 0.81 μM. At L-Asp 
calix[4]arene concentrations of 0.16–0.81 μM, the filtrates from the conductivity 
experiments were allowed to stand for 5–14 days over coverslips. 
 
The morphology of barium sulfate grown in the presence of the glutamic acid 
derivative 7b was similar to those grown in the presence of 7a. For low concentrations 
of the additive (<0.39 μM), the barium sulfate was polycrystalline and the constituents 
of the clusters had a lengthened c-axis (Figure 7a–c), similar to that crystallised in the 
presence of the lower-rim analogue 7.  At higher concentrations (>0.78 μM), the 
presence of the glutamic acid derivative 7b, like 7a, resulted in barium sulfate particles 
that were rounded and did not have a rectangular shape (Figure 7d–e).  
(a) (b) (c) 




   
   
Figure 7. SEM micrographs showing the impact on the morphology of barium sulfate 
by L-Glu calix[4]arene 7b at, (a) 0 μM (control), (b) 0.08 μM, (c) 0.39 μM, (d) 
0.78 μM, (e) 0.78 μM, and (f) 2.33 μM. Where the L-Glu calix[4]arene concentration 
was at 2.33 μM, the filtrate from the conductivity experiments were allowed to stand 
over a coverslip for 14 days. 
2.3.3 Impact on nucleation kinetics 
The induction time for barium sulfate crystallisation was determined by a light 
scattering method,(61) as it can not be reliably determined from desupersaturation 
curves.(62) The results indicated that the presence of additives lengthened the induction 
time compared with control experiments. Mullin(62) defines the induction time to 
include the time taken to form stable nuclei and the growth of the nuclei to a measurable 
size. Therefore, an increase in the induction time can be an indication of an increase in 
time required to form stable nuclei and/or time required for the nuclei to grow to a 
detectable size. It has also been found that increases in induction time can be related to 
increases in the surface free energy of the critical nuclei. This implies that additives that 
impact on the induction time are adsorbing onto the critical nuclei and altering their 
surface energies. 
(a) (b) (c) 
(d) (e) (f) 
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The results (Table 1) showed that the amino acid functionalised calixarene 
additives lengthened the induction time of barium sulfate. The aspartic acid derivative 
7a (Figure 8) doubled the induction time for barium sulfate at a concentration of 
0.04 μM. The glutamic acid derivative 7b (Figure 9) was less potent requiring ten times 
the additive level of 7a to induce a doubling of the induction time. Thus, these additives 
have an impact on both the nucleation events and crystal growth phase of barium 
sulfate. This suggests that both the L-aspartic acid and L-glutamic calixarene additives 
acted as inhibitors of both bulk nucleation and crystal growth. 
Table 1. Approximate induction times for the autonucleation of BaSO4 in the presence 






None (control) — 100 
L-Asp calix[4]arene 7a 0.04 200 
L-Glu calix[4]arene 7b 0.39 250 
L-Glu calix[4]arene 7b 0.58 700 




Figure 8. Determination of induction time for autonucleated barium sulfate in the 
presence of L-aspartic acid functionalised calix[4]arenes (7a). Absorbance of reaction 
solution measured overtime with additive levels at 0 μM of additive (control) and 
0.04 μM (0.05 ppm). 
 
Figure 9. Determination of induction time for autonucleated barium sulfate in the 
presence of L-glutamic acid functionalised calix[4]arene (7b). Absorbance of reaction 
solution measured overtime with additive levels from 0 μM of additive (control) to 




The amino acid functionalised calixarenes, 7a–c, had an impact on the crystallisation of 
model mineral systems, calcium carbonate and barium sulfate. The aspartic acid 
functionalised calixarene 7a appeared to affect the morphology of calcium carbonate 
more than the glutamic acid derivative 7b. Whilst 7b appeared to behave similarly to its 
lower-rim counter part in the crystallisation of calcium carbonate, 7a resulted in a 
different calcite morphology compared with its lower-rim analogue. The iminodiacetic 
acid derivative 7c required a higher additive level to alter the calcite morphology. 
Barium sulfate grown in the presence of 7a and 7b gave similar morphologies. The 
kinetics of crystallisation, however suggested that the aspartic calixarene 7a was a more 
potent crystal growth inhibitor than the glutamic calixarene 7b. The aspartic derivative 
7a was also a more potent barium sulfate growth inhibitor than the lower-rim analogue; 
7b showed similar potency to its lower-rim analogue. The higher activity of the upper 
rim aspartic acid derivatives 7a compared to lower rim analogs 5 could be related to the 
different rigidity and bite-distance of the chelating carboxylic groups. In general, it was 
also confirmed that the high density of carboxylate groups given by the simultaneous 
presentation of aspartic/glutamic residues onto a cone-calix[4]arene greatly enhance the 
inhibition of calcite or barite crystal growth in solution.  
4 Experimental 
4.1 General remarks 
Reagents were used as purchased from the manufacturer or supplier. MilliQ water, 
having a resistance of 0.055 cm/Ω, was used throughout crystallisation experiments.  
Solvents for reactions and column chromatography were purified according to 
Armarego and Chai.(63) 
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Column chromatography was performed on Merck silica gel 60 (230–400 mesh). 
Reactions were monitored by TLC on aluminium backed Merck silica gel 60 F245 with 
detection by UV (for aromatic compounds), 1% FeCl3 solution (for phenolic 
compounds), Brady’s reagent(64) (for aldehydes), iodine vapour (general purpose) 
and/or 1% potassium permanganate solution (general purpose). 





H 200 MHz, 
13
C 50 MHz) or a Bruker Avance
TM





C 100 MHz) spectrometer. NMR spectra were referenced to their respective 
solvents:(65, 66) chloroform-d (CDCl3, 
1
H, δ7.26 ppm; 
13
C, δ77.16 ppm); dimethyl 
sulfoxide-d6 (CD3SOCD3, 
1
H, δ2.50 ppm; 
13
C, δ39.52 ppm). NMR signal assignments 


















Multiplicity is assigned as follows: s = singlet, d = doublet, t = triplet, q = quartet, sxt = 
sextet, br = broad. 
Attenuated total reflectance Fourier Transform infrared (ATR-FT-IR) spectra were 
acquired on a PerkinElmer Spectrum 100 series spectrometer with a Universal ATR 
sampling accessory fitted with a ZnSe/diamond composite crystal. Spectra were 
recorded at a resolution of 4 cm
−1
 in the range of 4000–650 cm
−1
 with 16 scans 
accumulated. ATR correction was applied to the spectra. 
Elemental analysis was performed by the Central Science Laboratory, University of 
Tasmania. 
Melting ranges of solid samples were determined using a Barnstead/Electrothermal 
digital melting point apparatus (model 9100) at atmospheric pressure. Melting ranges 
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were measured in duplicate then averaged. 25,26,27,28-tetra-n-propoxycalix[4]arene-
5,11,17,23-tetracarbonyl chloride (9) was prepared according to literature.(41)  
4.2 Preparation of amino acid functionalised calixarenes for crystal 
growth modification studies 
4.2.1 Preparation of 25,26,27,28-tetra-n-propoxycalix[4]arene-5,11,17,23-
tetrakis-{(2S)-2-[(carbonyl)amino]}butanedioic acid diethyl ester 
(13a) 
A solution of L-aspartic acid diethyl ester hydrochloride (502 mg, 2.22 mmol) 
and triethylamine (0.61 mL, 440 mg, 4.35 mmol) dissolved in dichloromethane (15 mL) 
was added dropwise to a cold stirring solution of the acid chloride 9 (413 mg, 
0.49 mmol) dissolved in dichloromethane (15 mL) over 15 minutes. The reaction 
mixture was stirred at room temperature under an argon atmosphere over the weekend. 
The reaction mixture was diluted with hydrochloric acid (1 m, 30 mL) and stirred for 30 
minutes. The organic phase was separated and washed with hydrochloric acid 
(2×15 mL) then saturated sodium chloride (30 mL), dried (MgSO4), and concentrated in 
vacuo. Purification of the brown residue by column chromatography 
[dichloromethane/acetone (9:1, v/v)] afforded a glassy yellow solid (318 mg, 
0.22 mmol, 44% yield) which crystallised on standing: mp 120–130 °C (material 
crystallised from glassy material); 
1
H NMR (400 MHz, CDCl3) δ 7.16 (d, J = 2.1 Hz, 
4H, Ar–H), 7.04 (d, J = 2.1 Hz, 4H, Ar–H), 7.01 (d, J = 7.9 Hz, 4H, N–H), 4.88 
(apparent dt, 4H, NCH), 4.46 (d, J = 13.6 Hz, 4H, Hax, Ar–CH2–Ar), 4.25–4.09 
(overlapped m, 16H, OCH2CH3), 3.88 (t, J = 7.5 Hz, 8H, OCH2CH2), 3.27 (d, J = 
13.6 Hz, 4H, Heq, Ar–CH2–Ar), 3.02 (dd, J = 4.4, 16.7 Hz, 4H, H′, CH2C=O), 2.94 (dd, 
J = 5.4, 16.7 Hz, 4H, H″, CH2C=O), 1.90 (sxt, J = 7.5 Hz, 8H, OCH2CH2), 1.25 





NMR (100 MHz, CDCl3) δ 171.4 (C=O, ester), 171.2 (C=O, ester), 167.0 (C=O, 
amide), 159.6 (C–O, Ar), 135.0 (C–CH2, Ar), 134.8 (C–CH2, Ar), 128.3 (C–C=O, Ar), 
128.1 (C–H, Ar), 127.2 (C–H, Ar), 77.2 (overlapped with CDCl3, OCH2CH2), 61.8 
(OCH2CH3), 61.1 (OCH2CH3), 49.3 (NCH), 36.5 (CH2C=O), 31.2 (Ar–CH2–Ar), 23.3 
(OCH2CH2), 14.30 (OCH2CH3), 14.25 (OCH2CH3), 10.4 (OCH2CH2CH3); IR (ATR) 
ν̅max  (cm
–1
) 3347 (N–H), 1732 (C=O, ester), 1657 (C=O, amide), 1197 (C–O). Anal. 
Calcd for C76H100N4: C, 62.80; H, 6.93; N, 3.85%. Found: C, 62.54; H, 6.75; N, 3.64%. 
4.2.2 Preparation of 25,26,27,28-tetra-n-propoxycalix[4]arene-5,11,17,23-
tetrakis-{(2S)-2-[(carbonyl)amino]}pentanedioic acid diethyl ester 
(13b) 
(a) The acid chloride (94) (519 mg, 0.62 mmol) was treated with a solution of L-
glutamic acid diethyl ester hydrochloride  (978 mg, 4.08 mmol) and triethylamine (1.40 
mL, 10.5 mmol) as above, and allowed to stir at room temperature for six days. Work-
up, followed by chromatography (dichloromethane/ acetone (9:1, v/v) and 0.5 v/v% 
triethylamine) afforded a glassy yellow solid (320 mg, 0.21 mmol, 34% yield) which 
crystallised on standing: mp 121–136 °C (material crystallised from glassy material); 
1
H 
NMR (400 MHz, CDCl3) δ 7.16 (d, J = 2.2 Hz, 4H, Ar–H), 7.10 (d, J = 2.2 Hz, 4H, Ar–
H), 6.83 (d, J = 7.0 Hz, 4H, N–H), 4.59 (apparent dt, 4H, NCH), 4.46 (d, J = 13.6 Hz, 
4H, Hax, Ar–CH2–Ar), 4.27–4.15 (m, 8H, OCH2CH3), 4.15–4.02 (m, 8H, OCH2CH3), 
3.38 (t, J = 7.5 Hz, 8H, OCH2CH2), 3.26 (d, J = 13.6 Hz, Heq, Ar–CH2–Ar), 2.50–2.34 
(m, 8H, CH2C=O), 2.31–2.17 (m, 4H, H′, NCHCH2), 2.12–1.99 (m, 4H, H″, NCHCH2), 
1.90 (sxt, J = 7.5 Hz, 8H, OCH2CH2), 1.28 (t, J = 7.1 Hz, 12H, OCH2CH3), 1.21 (t, J = 
7.2 Hz, 12H, OCH2CH3), 0.99 (t, J = 7.5 Hz, 12H, OCH2CH2CH3); 
13
C NMR 
(100 MHz, CDCl3) δ 173.4 (C=O, ester), 172.1 (C=O, ester), 167.3 (C=O, amide), 
159.4 (C–O, Ar), 135.0 (C–CH2, Ar), 134.9 (C–CH2, Ar), 128.5 (C–C=O, Ar), 127.8 
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(C–H, Ar), 127.7 (C–H, Ar), 77.2 (overlapped with CDCl3, OCH2CH2), 61.6 
(OCH2CH3), 60.7 (OCH2CH3), 52.5 (NCH), 31.2 (Ar–CH2–Ar), 30.6 (CH2C=O), 27.4 
(NCHCH2), 23.3 (OCH2CH2), 14.30 (OCH2CH3), 10.4 (OCH2CH2CH3); IR (ATR) ν̅max   
(cm
–1
) 3382 (N–H), 1733 (C=O, ester), 1645 (C=O, amide), 1190 (C–O). Anal. Calcd 
for C80H108N4: C, 63.64; H, 7.21; N, 3.71%. Found: C, 63.48; H, 7.53; N, 3.66%. 
(b) Dicyclohexylcarbodiimide (153 mg, 0.74 mmol), N-hydroxybenzotriazole 
(95 mg, 0.70 mmol), triethylamine (0.25 mL, 1.8 mmol) and diethyl glutamate 
hydrochloride (454 mg, 1.89 mmol) were added to a solution of the calixarene acid (8) 
(107 mg, 0.14 mmol) in dichloromethane/dimethylformamide (4:1, 10 mL) and the 
reaction mixture stirred at room temperature (48 h). Dicyclohexylurea was removed by 
filtration and the filtrate treated with dilute hydrochloric acid (10 mL of 0.5 M). The 
organic layer was then washed with water (2 x 20 mL), dried (Na2SO4) and 
concentrated.  Chromatography (dichloromethane/acetone 9:1) then afforded 13b (86 
mg, 41%) as a colourless glass.  
(c) Triethylamine (0.22 mL, 1.6 mmol) and diethyl glutamate hydrochloride 
(385 mg, 1.61 mmol) were added to a stirred suspension of the calixarene acid (8) (155 
mg, 0.20 mmol) in dichloromethane (15 mL).  When complete solublisation had 
occurred, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 
(416 mg, 1.1 mmol) and triethylamine (0.22 mL, 1.6 mmol) were added and the reaction 
mixture stirred at room temperature (6 h). During the first 30 minutes the pH was 
checked frequently and triethylamine added as required to maintain it was 
approximately 8.5. The reaction was quenched by the addition of hydrochloric acid (15 
mL of 1 M), the organic layer separated, washed with sodium bicarbonate solution (15 
mL of 5%) and brine (15 mL), dried (Na2SO4) and concentrated. Chromatography 
(dichloromethane/acetone 9:1) then afforded 13b (160 mg, 53%) as a colourless glass. 
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4.2.3 Preparation of 25,26,27,28-tetra-n-propoxycalix[4]arene-5,11,17,23-
tetrakis-2,2’-[(carbonyl)imino]diacetic acid diethyl ester (13c) 
A solution of 2,2’-[(carbonyl)imino]diacetic acid diethyl ester hydrochloride 
(1.27 g, 5.65 mmol) and triethylamine (2.00 mL, 1.52 g, 15.0 mmol) dissolved in 
dichloromethane (15 mL) was added dropwise to a cold stirring solution of 9 (565 mg, 
0.67 mmol) dissolved in dichloromethane (10 mL) over 15 minutes. The reaction 
mixture was stirred at room temperature under a nitrogen atmosphere over three days. 
The reaction mixture was diluted with dichloromethane (25 mL) and washed with 
hydrochloric acid (1 m, 3×25 mL), saturated sodium chloride (25 mL), dried (Na2SO4), 
and concentrated in vacuo. Purification of the brown residue by column 
chromatography [dichloromethane/acetone (9:1, v/v)] afforded a glassy yellow solid 
(296 mg, 0.20 mmol, 30% yield) which crystallised on standing: mp 110–121 °C 
(material crystallised from glassy material); 
1
H NMR (400 MHz, CDCl3) δ 6.95 (s, 8H, 
Ar–H), 4.46 (d, J = 13.3, 4H, Hax, Ar–CH2–Ar), 4.33–4.07 (overlapped m, OCH2CH3 
and NCH2), 3.90 (t, J = 7.7 Hz, 8H, OCH2CH2), 3.17 (d, J = 13.3 Hz, 8H, Heq, Ar–CH2–
Ar), 1.92 (sxt, J = 7.7 Hz, 8H, OCH2CH2CH3), 1.27 (apparent br t, 24H, OCH2CH3), 
0.99 (J = 7.7 Hz, 12H, OCH2CH2CH3); 
13
C NMR (100 MHz, CDCl3) δ 171.6 (C=O), 
169.6 (C=O), 169.2 (C=O), 158.3 (C–O, Ar), 134.7 (C–CH2, Ar), 128.2 (C–C=O, Ar), 
128.3 (C–H, Ar), 61.7, 61.1 (OCH2CH3), 77.2 (overlapped with CDCl3, OCH2CH2), 
52.2, 48.1 (NCH2C=O), 31.4 (Ar–CH2–Ar), 23.2 (OCH2CH2CH3), 14.5, 14.3 
(OCH2CH3), 10.4 (OCH2CH2CH3); IR (ATR) ν̅max (cm
–1
) 1738 (C=O, ester), 1645 
(C=O, amide), 1183 (C–O). Anal. Calcd for C76H100N4: C, 62.80; H, 6.93; N, 3.85%. 
Found: C, 62.80; H, 7.00; N, 3.68%. 
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4.2.4 Preparation of 25,26,27,28-tetrapropoxycalix[4]arene-5,11,17,23-
tetrakis-{(2S)-2-[(carbonyl)amino]}butanedioic acid (7a) 
A solution of potassium carbonate (350 mg, 2.53 mmol) in water (2 mL) was 
added to a stirred solution of (13a) (286 mg, 0.20 mmol) in methanol (25 mL) at 40–
50 °C. The reaction mixture was stirred for 2 hours, cooled to room temperature, and 
concentrated in vacuo. The residue was diluted with water (30 mL), acidified with 
hydrochloric acid (3 m, ~2 mL) to pH ~1, and extracted with ethyl acetate (4×15 mL). 
The ethyl acetate extracts were combined, washed with water (30 mL) then saturated 
sodium chloride (30 mL), dried (Na2SO4), and concentrated in vacuo. This gave a solid 
(160 mg, 0.13 mmol, 66% yield): mp >240 °C dec; 
1
H NMR (400 MHz, CD3SOCD3) δ 
12.50 (br s, 5H, COOH),
* 
8.74–8.24 (m, 4H, N–H), 7.59–7.19 (m, 8H, Ar–H), 4.74–
4.54 (m, 4H, NCH), 4.43, (d, J = 12.9, 4H, Hax, Ar–CH2–Ar), 4.02–3.92 (m, 4H, 
OCH2), 3.36 (overlapped with HOD, Heq, Ar–CH2–Ar), 2.93–2.55 (m, NCHCH2C=O), 
1.92 (sxt, J = 7.5 Hz, 8H, OCH2CH2CH3), 1.04–0.90 (m, 12H, CH3); 
13
C NMR 
(100 MHz, CD3SOCD3) δ 172.6 (C=O, carboxylic acid), 172.0 (C=O, carboxylic acid), 
165.7 (C=O, amide), 158.7 (C–O, Ar), 134.0 (C–CH2, Ar), 128.1 (overlapped, C–H, Ar 
and C–C=O, Ar), 76.7 (OCH2), 49.3 (NCH), 35.9 (CH2C=O), 30.7 (Ar–CH2–Ar), 22.7 
(OCH2CH2), 10.1 (CH3); IR (ATR) ν̅max  (cm
–1
) 3340 (O–H), 1720 (C=O, carboxylic 
acid), 1626 (C=O, amide), 1205 (C–O). 
4.2.5 Preparation of 25,26,27,28-tetra-n-propoxycalix[4]arene-5,11,17,23-
tetrakis-{(2S)-2-[(carbonyl)amino]}pentanedioic acid (7b) 
An aqueous solution of potassium hydroxide (1.92 m, 925 μL, 1.78 mmol) was 
added to a solution of 13b (320 mg, 0.21 mmol) in methanol (20 mL) and stirred at 
room temperature for 6 hours. The reaction mixture was acidified with hydrochloric 
acid (3 m, ~1 mL), concentrated in vacuo, and the residue was diluted with water 
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(10 mL) and ethyl acetate (10 mL). The aqueous phase was separated and extracted with 
ethyl acetate (3×10 mL). The ethyl acetate extracts were combined, washed with 
saturated sodium chloride (20 mL), dried (Na2SO4), and concentrated in vacuo. This 
gave a yellow solid (273 mg, 0.21 mmol, >98%): mp 121–140 °C; 
1
H NMR (400 MHz, 
CD3SOCD3) δ 12.40 (b s, 4H, COOH),
* 
8.55–8.08 (m, 4H, N–H), 7.60–7.20 (m, 8H, 
Ar–H), 4.44 (d, J = 12.8 Hz, 4H, Hax, Ar–CH2–Ar), 4.35–4.17 (m, 4H, NCH), 4.02–3.81 
(m, 8H, OCH2), 3.37 (overlapped with HOD, Heq, Ar–CH2–Ar), 2.45–2.27 (m, 8H, 
CH2C=O), 2.12–1.83 (overlapped m, 16H, NCHCH2 and OCH2CH2), 1.06–0.90 (m, 
12H, CH3); 
13
C NMR (100 MHz, CD3SOCD3) δ 173.3 (C=O, carboxylic acid), 172.9 
(C=O, carboxylic acid), 166.4 (C=O, amide), 158.6 (C–O, Ar), 134.0 (C–CH2, Ar), 
128.3 (C–C=O, Ar), 128.1 (C–H, Ar), 76.7 (OCH2), 52.1 (NCH), 30.6 (Ar–CH2–Ar), 
30.2 (CH2C=O), 25.9 (NCHCH2), 22.7 (OCH2CH2), 10.1 (CH3); IR (ATR) ν̅max  (cm
–1
) 
3352 (O–H), 1731 (C=O, carboxylic acid), 1633 (C=O, amide), 1202 (C–O). 
4.2.6 Preparation of 25,26,27,28-tetra-n-propoxycalix[4]arene-5,11,17,23-
tetrakis-2,2’-[(carbonyl)imino]diacetic acid (7c) 
A solution of potassium carbonate (212 mg, 1.53 mmol) in water (2 mL) was 
added to a stirred solution of 13c (178 mg, 0.12 mmol) in methanol (25 mL) at 40–
50 °C. The reaction mixture was stirred for 2 hours, cooled to room temperature, and 
concentrated in vacuo. The residue was diluted with water (30 mL), acidified with 
hydrochloric acid (3 m, ~1.5 mL) to pH ~2, and extracted with ethyl acetate (4×15 mL). 
The ethyl acetate extracts were combined, washed with saturated sodium chloride 
(30 mL), dried (Na2SO4), and concentrated in vacuo. This gave a solid (140 mg, 
0.11 mmol, 85% yield): mp >245 °C; 
1
H NMR (400 MHz, CD3SOCD3) δ 12.76 (br s, 
4H, COOH),
*
 7.48–6.30 (m, 8H, Ar–H), 4.36 (d, J = 13.2 Hz, 4H, Hax, Ar–CH2–Ar), 
4.20–3.59 (overlapped m, 24H, NCH2 and OCH2), 3.28 (overlapped with HOD, Heq, 
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Ar–CH2–Ar), 2.02–1.79 (m, 8H, OCH2CH2), 1.14–0.79 (m, 12H, CH3); 
13
C NMR 
(100 MHz, CDCl3) δ 170.3 (C=O, carboxylic acid), 169.8 (C=O, amide), 157.7 (C–O, 
AR), 134.5 (C–CH2, Ar), 128.0 (C–C=O, Ar), 1272 (C–H, Ar), 76.7 (OCH2), 48.3 
(NCH2), 30.4 (Ar–CH2–Ar), 22.7 (OCH2CH2), 10.1 (CH3); IR (ATR) ν̅max (cm
–1
) 3460 
(O–H), 1725 (C=O, carboxylic acid), 1196 (C–O). 
4.3 Calcium carbonate crystallisation experiments 
The impact of the synthesised crystal growth modifiers on the morphology of calcite 
was investigated using literature methods.(40, 47) Briefly, glass vials containing 
calcium chloride (7 mmol, 20 mL) with the appropriate concentration of additives and a 
microscope coverslip (10 mm diameter), were placed in a sealed desiccator (20 cm) 
along with a vial of ammonium carbonate. The vials were covered with Parafilm
®
, with 
pinholes to allow the diffusion of ammonia and carbon dioxide. After seven days, the 
microscope coverslips were recovered and dried. After gold coating, the crystals were 
examined under a scanning electron microscope (Zeiss Evo 40XVP). 
4.4 Barium sulfate crystallisation experiments 
The impact of the synthesised additives on autonucleated desupersaturation rate and 
morphology of barium sulfate were investigated by literature methods.(36, 40) Briefly, 
barium chloride (0.100 M, 500 μL, final Ba
2+
 concentration 0.249 mM) and the additive 
(as a solution, neutralised with sodium hydroxide) were added to milliQ water (200 mL) 
and allowed to equilibrate at 25 °C while stirred. Equivalent sodium sulfate (0.100 M, 
500 μL) was added to initiate autonucleation and the conductivity meter (WTW model 
LF 197) set to measure (the data was recorded by a computer). After 3–5 hours, the 
reaction mixture was filtered through a 0.2 μm filter membrane. If there was no 
decrease in the conductivity over the experiment period, the solution was placed in a 
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vial with a microscope coverslip and allowed to crystallise for 5 to 14 days. Filter 
membranes and microscope coverslips were dried, gold coated, and the morphology 
examined under a scanning electron microscope (Zeiss Evo 40XVP). The 
desupersaturation rate was determined from the linear region of the desupersaturation 
curve. 
Induction times were determined by a similar set-up to the desupersatuaration 
experiments. Barium chloride (0.100 M, 500 μL, final Ba
2+
 concentration 0.249 mm) 
and the additive (as a solution, neutralised with sodium hydroxide) were added to 
milliQ water (200 mL) and allowed to equilibrate at 25 °C while stirred. Equivalent 
sodium sulfate (0.100 M, 500 μL) was added to initiate crystallisation. The reaction 











 pump head (model 7518-00) at 250 rpm into a quartz flow cell. The 
absorbance at 900 nm was recorded by a GBC UV/VIS 916 spectrometer at 10 s 
intervals over 2 hours. The reaction mixture was filtered through a 0.2 μm filter 
membrane. Filter membranes were dried, gold coated, and the morphology examined 
under a scanning electron microscope (Zeiss Evo 40XVP). Induction times were 
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